Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN510713 in Combination With mFOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT07114861Phase 2Recruiting
- Sponsor
- New Cancer Cure-Bio Co., Ltd
- Start
- Dec 2025
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of KN-510 and KN713 in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by New Cancer Cure-Bio Co., Ltd. Primary endpoints: Adverse Events at 12 months and Dose-Limiting Toxicities at 4 weeks. Started Dec 2025; status: recruiting.
02
Drugs
KN-510KN713
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07114861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07114861.